APN Results Bullish

ASPEN PHARMACARE HOLDINGS LIMITED - Unaudited condensed interim Group financial results for the six months ended 31 December 2025

Aspen Pharmacare Holdings Limited
Free preview

What this filing means

Aspen reported a transitional H1 2026 with a 35% HEPS decline due to restructuring and mRNA contract losses, but maintains guidance for double-digit FY 2026 growth and significant debt elimination via the APAC divestment.

Bull case

  • Commercial Pharmaceuticals, the Group's core segment, delivered robust 11% normalised EBITDA growth at constant exchange rates (CER), supported by strong demand for Mounjaro®.
  • The APAC Divestment of AUD 2.37 billion is expected to effectively eliminate most of the Group's net debt, drastically improving balance sheet flexibility.

Bear case

  • Headline earnings per share (HEPS) fell 35% to 417.4 cents, heavily impacted by R695 million in restructuring costs and the loss of the mRNA contract.

Unlock the full analysis

Free during launch. Sign in to read the complete breakdown.

  • Full bull / bear breakdown
  • Decision framework
  • Citations & sources
  • Price autopsy
Sign in for full analysis
Category
Results
Published
Mar 3, 2026

Related filings